^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
cobas® HPV test

Company:
Roche
Type:
FDA Approved (PMA)
Related tests:
Evidence

News

4d
Addressing Cervical Cancer Screening Disparities: At-Home Self-Collection Among LGBQ+ Populations. (PubMed, Cancer Control)
Qualitative comments emphasized privacy and reduced distress, including trauma- and dysphoria-related concerns.ConclusionAt-home SC is a clinically valid, usable, and strongly preferred CCS option, particularly among LGBQ+ populations who experience disproportionate barriers to speculum-based CCS. Broader adoption of FDA-authorized at-home SC paired with telehealth will enable future impact assessment to reduce persistent disparities in CCS for LGBQ+ populations.
Journal
|
cobas® HPV test
12d
HPV Detection in Clinician-Collected, Self-Collected Vagina, Urine, and Menstrual Blood Samples. (PubMed, J Low Genit Tract Dis)
Self-collected vaginal, urine, and menstrual blood samples show moderate to good concordance with clinician-collected samples for HrHPV detection. However, only self-collected vaginal samples demonstrate comparable sensitivity and specificity for detecting HSIL.
Journal
|
cobas® HPV test
26d
HPV Prevalence Among Inuit Women in Northern Quebec, Canada: A Pre- and Post-Vaccination Analysis. (PubMed, J Low Genit Tract Dis)
The quadrivalent HPV vaccine has reduced HPV 16/18 prevalence in the targeted younger population. Continued surveillance is warranted, particularly for nonvaccine high-risk types.
Journal
|
cobas® HPV test
|
Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine)
2ms
Genotype-specific prevalence of high-risk human papillomavirus among cytologically normal women in Taiwan. (PubMed, Taiwan J Obstet Gynecol)
This study provided updated hrHPV prevalence estimates that may inform age-based screening strategies and underscored the need for genotype surveillance and risk-based triage approaches.
Journal
|
cobas® HPV test
3ms
Journal • Head-to-Head
|
cobas® HPV test
3ms
Comparison of Whole-Viral Genome Sequencing and PCR-based assay for Anal HPV Detection to Inform Clinical Implementation. (PubMed, J Virol Methods)
In addition, WGS-based identification of HPV16 sub-lineages demonstrated that the composite A1, A2, A4, and C1 sub-lineages were associated with a higher risk of abnormal cytology compared to other HPV16 sub-lineages. WGS can further delineate the natural history of anal HR-HPV and their sub-lineages in populations at high-risk for HPV acquisition.
Journal
|
cobas® HPV test
3ms
Performance of a New Brazilian Self-Sampling Device for High-Risk Human Papillomavirus Screening. (PubMed, Asian Pac J Cancer Prev)
The COARI® self-sampling device demonstrated reliable and effective performance for hrHPV detection and partial typing, showing strong potential to increase access to and coverage of cervical cancer screening in Brazil. Further studies with larger and more diverse populations are needed to validate these findings and inform public health implementation.
Journal
|
cobas® HPV test
3ms
HPV Vaccination and HPV Outcomes After LEEP: A Retrospective Population-Based Cohort Study from Northern Norway, 2022-2024. (PubMed, Vaccines (Basel))
HPV vaccination before the first post-treatment follow-up was associated with lower HPV positivity after LEEP. As this outcome is a surrogate endpoint and residual confounding is possible, studies with standardized follow-up and long-term clinical endpoints are needed.
Retrospective data • Journal
|
cobas® HPV test
4ms
High throughput HPV genotyping by next generation sequencing for detection of 28 HPV types and 13 sexually transmitted infections: A first community-based cervical cancer screening study from India. (PubMed, Diagn Microbiol Infect Dis)
A substantial proportion of women with abnormal cytology in this community cohort harboured non-HPV16 and HPV18 high-risk infections, highlighting the importance of extended HPV genotyping. NGS-based HPV genotyping was concordant with the comparator assay used and had simultaneous STI identification, supporting its potential utility as a comprehensive tool for community-based cervical cancer screening and risk stratification.
Journal • Next-generation sequencing
|
cobas® HPV test
4ms
Advancing Cervical Cancer Screening Through the Emergency Department - IIS (clinicaltrials.gov)
P=N/A, N=200, Active, not recruiting, University of Rochester | Recruiting --> Active, not recruiting
Enrollment closed
|
cobas® HPV test
4ms
Comparative efficacy, feasibility and acceptability of HPV DNA testing on first-void urine versus self-collected vaginal samples: a real-world study in a resource-limited setting. (PubMed, BMJ Glob Health)
HPV testing using FVU demonstrates high agreement with vaginal self-sampling, comparable accuracy in detecting CIN2+ lesions and greater acceptability among women. This method is feasible and well-suited for cervical cancer screening in resource-limited settings.
Clinical • Journal • Real-world evidence
|
cobas® HPV test
4ms
Evaluation of Cycle Threshold (Ct) Values for Detecting High-Risk HPV in Self-Collected Vaginal Samples as a Triage Method to Colposcopy. (PubMed, Diagnostics (Basel))
For self-collected vaginal samples of hrHPV-positive women, the Ct value may be used as a triage method to colposcopy. As Ct values inversely reflect the viral loads, they are lower in high-grade CIN and/or carcinoma.
Journal
|
cobas® HPV test